Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Yuki Fujii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4231-9955; OpenAlex author ID A5070655967, A5076443486. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 9

  1. Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/cas.70533↗
  2. A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm. Co-author DOI 10.1007/s12328-025-02098-y↗
  3. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Co-author DOI 10.1186/s12935-025-03894-9↗
  4. Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17203287↗
  5. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. Co-author DOI 10.1016/j.pan.2023.10.018↗
  6. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.18926/amo/65974↗
  7. Diagnostic Ability of Convex-Arrayed Endoscopic Ultrasonography for Major Vascular Invasion in Pancreatic Cancer. Co-author DOI 10.5946/ce.2018.163↗
  8. Predictive Value of Localized Stenosis of the Main Pancreatic Duct for Early Detection of Pancreatic Cancer. Co-author DOI 10.5946/ce.2019.018↗
  9. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in … Co-author DOI 10.18632/oncotarget.26117↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigeru Horiguchi · 6 shared papers, 2019–2026 · strength 1.13
  2. Kazuyuki Matsumoto · 6 shared papers, 2019–2025 · strength 1.10
  3. Motoyuki Otsuka · 5 shared papers, 2023–2026 · strength 1.05
  4. Kosei Takagi · 4 shared papers, 2025–2026 · strength 0.90
  5. Koichiro Tsutsumi · 4 shared papers, 2023–2026 · strength 0.79
  6. Kazuya Yasui · 3 shared papers, 2025–2026 · strength 0.66
  7. Hironari Kato · 4 shared papers, 2019–2025 · strength 0.60
  8. Hiroyuki Terasawa · 3 shared papers, 2023–2026 · strength 0.55
  9. Daisuke Uchida · 3 shared papers, 2019–2026 · strength 0.45
  10. Yasuo Nagai · 2 shared papers, 2025 · strength 0.44
  11. Takeyoshi Nishiyama · 2 shared papers, 2025 · strength 0.44
  12. Toshiyoshi Fujiwara · 2 shared papers, 2025 · strength 0.44
  13. Tatsuya Kikuchi · 2 shared papers, 2023–2026 · strength 0.36
  14. Ryosuke Sato · 1 shared paper, 2025 · strength 0.25
  15. Soichiro Ako · 1 shared paper, 2026 · strength 0.22
  16. Hideaki Kinugasa · 1 shared paper, 2026 · strength 0.22
  17. Kokichi Miyamoto · 1 shared paper, 2025 · strength 0.19
  18. Yuzo Umeda · 1 shared paper, 2025 · strength 0.19
  19. Kazuhiro Yoshida · 1 shared paper, 2025 · strength 0.19
  20. Ryuichi Yoshida · 1 shared paper, 2025 · strength 0.19
  21. Shinichiro Muro · 1 shared paper, 2019 · strength 0.09
  22. Hiroyuki Okada · 1 shared paper, 2019 · strength 0.09
  23. Tatsuzo Mizukami · 1 shared paper, 2018 · strength 0.08
  24. Fumihiko Matsuzawa · 1 shared paper, 2018 · strength 0.08
  25. Takahiro Einama · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.